Cancer‑Associated Venous Thromboembolism (VTE) Risk Factors

1. Tumor‑Specific Risk

• Pancreatic adenocarcinoma and primary brain tumors confer the highest VTE risk among all malignancies – the National Comprehensive Cancer Network (NCCN) identifies these two tumor types as the most thrombogenic cancers. 1
• Gastric, renal, lung, ovarian, bladder, and testicular cancers are associated with significantly elevated VTE rates compared with lower‑risk malignancies, according to NCCN guideline data. 2
• Adenocarcinomas carry a higher VTE risk than squamous cell carcinomas across tumor sites (e.g., gastric, lung, ovarian), as reported by NCCN. 3
• High‑grade non‑Hodgkin lymphoma markedly increases DVT risk, most often due to tumor‑related venous compression; NCCN classifies this as a high‑risk hematologic malignancy. 1
• Patients with high‑grade lymphoma have a greater VTE risk than those with low‑grade disease (NCCN). 2
• Acute promyelocytic leukemia (APL) carries a particularly high thrombotic risk relative to other leukemias (NCCN). 3
• Multiple myeloma patients receiving immunomodulatory drug regimens (thalidomide‑ or lenalidomide‑based) together with high‑dose dexamethasone, anthracycline, or multi‑agent chemotherapy experience a dramatic amplification of VTE risk (NCCN). 1
• Breast cancer has a relatively low baseline VTE risk compared with most other cancers, but metastatic breast cancer raises VTE risk approximately six‑fold versus localized disease (NCCN). 2

2. Disease Extent

• Distant metastases are the single strongest disease‑related VTE risk factor, conferring an adjusted odds ratio of ~19.8 for VTE compared with localized disease (NCCN). 1

3. Treatment‑Related Amplifiers

• Active chemotherapy increases VTE risk about 6.5‑fold across cancer types (Praxis Medical Insights). 5
• Anti‑angiogenic and immunomodulatory agents—including thalidomide, lenalidomide, and bevacizumab—substantially raise DVT risk (Praxis Medical Insights). 5
• Hormonal therapies such as tamoxifen and oral contraceptives elevate VTE incidence (Praxis Medical Insights). 6
• Erythropoiesis‑stimulating agents are linked to increased thrombotic events (Praxis Medical Insights). 5

4. Temporal Factors

• The first three months after cancer diagnosis represent the period of maximal thrombotic risk for all tumor types (Praxis Medical Insights). 6
• A recent cancer diagnosis independently increases VTE risk regardless of tumor type (NCCN). 1

5. Epidemiologic Impact

• Cancer accounts for roughly 20 % of all community VTE cases, underscoring its public‑health significance (NCCN). 2

All statements are derived from guideline‑level evidence (NCCN) or high‑quality clinical reviews (Praxis Medical Insights). The strength of evidence is “guideline‑based” where NCCN citations are used, and “expert consensus/high‑quality review” for Praxis citations.